


JC17 Rec'd PCT/PTO 13 JUN 2005

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

V, X, W, Y and Z are each independently N or CR₁, with the proviso that at least one of V and X is N;

U is N or CR₂, with the proviso that if V and X are N, then U is CR₂;

R₁ is independently selected at each occurrence from hydrogen, halogen, hydroxy, cyano, amino, -COOH, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkoxycarbonyl, haloC₁-C₆alkoxy and mono- and di-(C₁-C₆alkyl)amino;

R₂ is:

(i) hydrogen, halogen, cyano or nitro; or

(ii) a group of the formula -R_c-M-A-R_y, wherein:

R_c is C₀-C₃alkyl, C₂-C₃alkenyl or C₂-C₃alkynyl, or is joined to R_y or R_z to form a 4- to 10-membered carbocycle or heterocycle that is substituted with from 0 to 2 substituents independently selected from R_b;

M is a bond, O, S, SO, SO₂, C(=O), OC(=O), C(=O)O, O-C(=O)O, C(=O)N(R_z), N(R_z)C(=O), N(R_z)SO₂, SO₂N(R_z), N(R_z), OPO₂(OR_z) or PO₂(OR_z);

A is a bond or C₁-C₈alkyl substituted with from 0 to 3 substituents independently selected from R_b; and

R_y and R_z, if present, are:

(a) independently:

(i) hydrogen or -COOH; or

(ii) C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl, C₂-C₈alkanone, C₂-C₈alkyl ether, a 4- to 10-membered carbocycle or heterocycle, or joined to R_c to form a 4- to

10-membered carbocycle or heterocycle, each of which is substituted with
from 0 to 6 substituents independently chosen from R_b ; or

(b) joined to form a 4- to 10-membered carbocycle or heterocycle that is substituted
with from 0 to 6 substituents independently selected from R_b ;

Ar_1 and Ar_2 are independently selected from 5- to 10-membered carbocycles and heterocycles,
each of which is substituted with from 0 to 3 substituents independently selected from
groups of the formula LR_a ;

L is independently selected at each occurrence from a bond, O , $S(O)_m$, $C(=O)$, $OC(=O)$,
 $C(=O)O$, $O-C(=O)O$, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and
 $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2;
and R_x is independently selected at each occurrence from hydrogen and C_1 - C_8 alkyl;

R_a is independently selected at each occurrence from:

- (i) hydrogen, halogen, cyano and nitro; and
- (ii) C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, C_2 - C_8 alkyl ether, mono- and di- $(C_1$ -
 C_8 alkyl)amino and (3- to 10-membered heterocycle) C_0 - C_6 alkyl, each of which is
substituted with from 0 to 6 substituents independently selected from R_b ; and

R_b is independently chosen at each occurrence from:

- (i) hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo and $-COOH$; and
- (ii) C_1 - C_8 alkyl, C_1 - C_8 alkenyl, C_1 - C_8 alkynyl, C_1 - C_8 alkoxy, C_1 - C_8 alkanoyl, C_2 -
 C_8 alkoxycarbonyl, C_2 - C_8 alkanoyloxy, C_1 - C_8 alkylthio, C_2 - C_8 alkyl ether, phenyl C_0 -
 C_8 alkyl, phenyl C_1 - C_8 alkoxy, mono- and di- $(C_1$ - C_6 alkyl)amino, $(SO_2)C_1$ - C_8 alkyl, (4- to 7-
membered heterocycle) C_0 - C_8 alkyl, $-PO_3(R_w)_2$ and $-OPO_3(R_w)_2$, wherein each R_w is
independently chosen from hydrogen, C_1 - C_8 alkyl, phenyl C_0 - C_8 alkyl and (5- to 7-
membered heterocycle) C_0 - C_8 alkyl;

wherein each of (ii) is substituted with from 0 to 3 substituents independently
chosen from hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo, $-COOH$, C_1 -
 C_8 alkyl, C_1 - C_8 alkoxy, C_1 - C_8 alkoxycarbonyl, C_2 - C_8 alkanoyloxy, C_1 - C_8 alkylthio, C_1 - C_8 alkyl
ether, hydroxy C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, phenyl C_0 - C_8 alkyl, mono- and di- $(C_1$ -
 C_6 alkyl)amino, $(SO_2)C_1$ - C_8 alkyl and (5- to 7-membered heterocycle) C_0 - C_8 alkyl; and

wherein the compound or pharmaceutically acceptable form thereof comprises at
least one carboxylic acid, phosphate or phosphonate group.

2. (Original) A compound or pharmaceutically acceptable form thereof according to claim 1, wherein U is C-R₂.

3. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein X and V are N.

4. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein V is N and X is CH.

5. (Original) A compound or pharmaceutically acceptable form thereof according to claim 2, wherein X is N and V is CH.

6. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 1-5~~claim 1, wherein Y is N and W and Z are each CH.

7. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 1-5~~claim 1, wherein Z is N and W and Y are each CH.

8. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 1-5~~claim 1, wherein W, Y and Z are each CH.

9. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 2-8~~claim 2, wherein R₂ is a group of the formula -R_c-M-A-R_y, R_c is C₁-C₃alkyl, and R₂ comprises a carboxylic acid, phosphate or phosphonate group.

10. (Original) A compound or pharmaceutically acceptable form thereof according to claim 9, wherein R₂ comprises a carboxylic acid group.

11. (Original) A compound or pharmaceutically acceptable form thereof according to claim 10, wherein the carboxylic acid group is a substituent of a heterocyclic ring.

12. (Original) A compound or pharmaceutically acceptable form thereof according to claim 9, wherein R₂ comprises a phosphate or phosphonate group.

13. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 1-12~~claim 1, wherein Ar₁ and Ar₂ are independently selected from phenyl and 6-membered aromatic heterocycles, each of which is substituted with 0, 1 or 2 substituents independently selected from groups of the formula LR_a.

14. (Original) A compound or pharmaceutically acceptable form thereof according to claim 13, wherein:

Ar₁ is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkoxy and haloC₁-C₆alkoxy; and
Ar₂ is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkyl, haloC₁-C₆alkyl, cyanoC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₂-C₆alkyl ether, C₁-C₆alkanoyl, -(SO₂)R_d, -N(R_x)S(O)_mR_d, and -N[S(O)_mR_x]S(O)_mR_d; wherein m is 1 or 2, R_x is hydrogen or C₁-C₆alkyl, and R_d is C₁-C₆alkyl, haloC₁-C₆alkyl, amino, mono- or di-(C₁-C₆alkyl)amino or a 5- to 10-membered, N-linked heterocyclic group, each of which R_d is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C₁-C₆alkyl)amino, C₁-C₄alkyl, haloC₁-C₄alkyl, C₁-C₄alkoxy and haloC₁-C₄alkoxy.

15. (Original) A compound or pharmaceutically acceptable form thereof according to claim 13, wherein:

Ar₁ is pyridyl, unsubstituted or substituted with halogen, cyano, C₁-C₄alkyl or haloC₁-C₄alkyl;
and
Ar₂ is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C₁-C₄alkyl, cyanoC₁-C₄alkyl, haloC₁-C₄alkyl, C₂-C₆alkyl ether and groups of the formula -(SO₂)R_d, wherein R_d is C₁-C₄alkyl or haloC₁-C₄alkyl.

16. (Original) A compound or pharmaceutically acceptable form thereof according to claim 13, wherein:

Ar₁ is phenyl, unsubstituted or substituted with halogen, cyano, C₁-C₄alkyl or haloC₁-C₄alkyl;
and

Ar₂ is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C₁-C₄alkyl, cyanoC₁-C₄alkyl, haloC₁-C₄alkyl, C₂-C₆alkyl ether and groups of the formula -(SO₂)R_d, wherein R_d is C₁-C₄alkyl or haloC₁-C₄alkyl.

17. (Original) A compound or pharmaceutically acceptable form thereof according to claim 13, wherein:

Ar₁ is pyridin-2-yl, 3-methyl-pyridin-2-yl, 3-trifluoromethyl-pyridin-2-yl or 3-halo-pyridin-2-yl;
and


Ar₂ is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

18. (Original) A compound or pharmaceutically acceptable form thereof according to claim 13, wherein:

Ar₁ is phenyl, 2-methyl-phenyl, 2-trifluoromethyl-phenyl or 2-halo-phenyl; and

Ar₂ is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

19. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 2-8~~claim 2, wherein the compound has the formula:



wherein:

R_c is C_0 - C_2 alkyl;

J is O or N(R_z);

R_z is:

(a) hydrogen;

(b) C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_2 - C_6 alkanone, C_2 - C_6 alkyl ether, or a 4- to 10-membered carbocycle or heterocycle, each of which is substituted with from 0 to 6 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, aminocarbonyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_8 alkoxycarbonyl, C_2 - C_8 alkanoyloxy, C_1 - C_8 alkylthio, C_2 - C_8 alkyl ether, and mono- and di-(C_1 - C_6 alkyl)amino; or

(c) joined to R_7 to form a 5- to 7-membered carbocycle or heterocycle that is substituted with from 0 to 6 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, -COOH, aminocarbonyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_8 alkoxycarbonyl, C_2 - C_8 alkanoyloxy, C_1 - C_8 alkylthio, C_2 - C_8 alkyl ether, and mono- and di-(C_1 - C_6 alkyl)amino;

E and F are independently CH or N;


R_3 represents from 0 to 2 substituents independently chosen from halogen, cyano, -COOH, C_1 - C_6 alkyl, halo C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, C_2 - C_6 alkyl ether, C_1 - C_6 alkanoyl, aminosulfonyl, mono- and di-(C_1 - C_8 alkyl)aminosulfonyl, (C_1 - C_8 alkyl)sulfonyl, amino, and mono- and di-(C_1 - C_6 alkyl)amino;

R_4 represents from 0 to 2 substituents independently chosen from halogen, cyano, C_1 - C_6 alkyl, halo C_1 - C_6 alkyl, amino, mono- and di-(C_1 - C_6 alkyl)amino, aminosulfonyl, and mono- and di-(C_1 - C_8 alkyl)aminosulfonyl; and

R_7 is:


(i) hydrogen;

- (ii) C₁-C₆alkyl, phenyl or 5- to 7-membered heterocycle, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, -COOH, aminocarbonyl, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₈alkoxycarbonyl, C₂-C₈alkanoyloxy, C₁-C₈alkylthio, C₁-C₈alkyl ether, mono- and di-(C₁-C₆alkyl)amino; or
- (iii) joined to R₂ to form an optionally substituted 5- to 7-membered heterocycle; and
- wherein the group designated:



comprises at least one carboxylic acid group.

20. (Original) A compound or pharmaceutically acceptable form thereof according to claim 19, wherein the compound has the formula:



wherein:

Y and Z are independently CH or N;

R₃ is halogen, cyano, -COOH, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, or mono- or di-(C₁-C₆alkyl)amino;

R₄ is halogen, cyano, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, or mono- or di-(C₁-C₆alkyl)amino; and


R₇ is (i) hydrogen; (ii) C₁-C₆alkyl substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, -COOH, C₁-C₆alkoxy, and mono- and di-(C₁-C₆alkyl)amino; or (iii) joined to R₂ to form an optionally substituted 5- to 7-membered heterocycle.

21. (Original) A compound or pharmaceutically acceptable form thereof according to claim 20, wherein J is O.

22. (Original) A compound or pharmaceutically acceptable form thereof according to claim 21, wherein R₇ is hydrogen.

23. (Original) A compound or pharmaceutically acceptable form thereof according to claim 20, wherein J is NH.

24. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 2-8~~ claim 2, wherein the compound has the formula:



wherein:

E and F are independently CH or N;

R₃ represents from 0 to 2 substituents independently chosen from halogen, cyano, -COOH, C₁-C₆alkyl, haloC₁-C₆alkyl, hydroxyC₁-C₆alkyl, C₂-C₆alkyl ether, C₁-C₆alkanoyl, aminosulfonyl, mono- and di-(C₁-C₈alkyl)aminosulfonyl, (C₁-C₈alkyl)sulfonyl, amino, and mono- and di-(C₁-C₆alkyl)amino;

R₄ represents from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, aminosulfonyl, and mono- and di-(C₁-C₈alkyl)aminosulfonyl;

each R₅ and R₆ is independently selected from hydrogen, hydroxy and C₁-C₈alkyl substituted with from 0 to 2 substituents independently selected from R_d;

R₇ is:


(i) -COOH; or

(ii) C₂-C₈alkoxycarbonyl, C₂-C₈alkanoyloxy, C₁-C₈alkoxy, mono- or di-(C₁-C₈alkyl)amino, or a 5- to 7-membered heterocycle, each of which is substituted with from 0 to 3 substituents independently chosen from R_d; or

(iii) -PO₃(R_w)₂ or -OPO₃(R_w)₂, wherein each R_w is independently chosen from:

(a) hydrogen; and
(b) C₁-C₈alkyl, phenylC₀-C₈alkyl and (5- to 7-membered heterocycle)C₀-C₈alkyl each of which is substituted with from 0 to 3 substituents independently chosen from R_d;
n is 0, 1, 2 or 3; and
each R_d is independently chosen from:
(i) halogen, hydroxy, cyano, amino, nitro, -COOH; and
(ii) C₁-C₄alkyl, C₁-C₄alkenyl, C₁-C₄alkynyl, C₁-C₄alkoxy, C₁-C₄alkanoyl, C₂-C₄alkoxycarbonyl, C₂-C₈alkanoyloxy, C₁-C₄alkylthio, C₂-C₄alkyl ether, and mono- and di-(C₁-C₄alkyl)amino, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino and -COOH; and
wherein R₇ is a carboxylic acid, phosphate or phosphonate group or at least one of R₅, R₆ or R₇ comprises at least one substituent selected from a carboxylic acid, phosphate or phosphonate group.

25. (Original) A compound or pharmaceutically acceptable form thereof according to claim 24, wherein the compound has the formula:



wherein:

Y and Z are independently CH or N;

R₃ is halogen, cyano, -COOH, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, or mono- or di-(C₁-C₆alkyl)amino;

R₄ is halogen, cyano, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, or mono- or di-(C₁-C₆alkyl)amino;


each R₅ and R₆ is independently hydrogen or methyl; and

R₇ is:

(i) -COOH;

- (ii) C₁-C₈alkoxy, C₁-C₈alkoxycarbonyl, pyrrolidine, piperidine, piperazine or morpholine, each of which is substituted with from 1 to 3 substituents independently chosen from R_d, wherein at least one occurrence of R_d is a carboxylic acid group; or
- (iii) -PO₃(R_w)₂ or -OPO₃(R_w)₂.

26. (Currently Amended) A compound or pharmaceutically acceptable form thereof according to ~~any one of claims 2-8~~claim 2, wherein the compound has the formula:



wherein:

E and F are independently CH or N;

R₃ represents from 0 to 2 substituents independently chosen from halogen, cyano, -COOH, C₁-C₆alkyl, haloC₁-C₆alkyl, hydroxyC₁-C₆alkyl, C₂-C₆alkyl ether, C₁-C₆alkanoyl, aminosulfonyl, mono- and di-(C₁-C₈alkyl)aminosulfonyl, (C₁-C₈alkyl)sulfonyl, amino, and mono- and di-(C₁-C₆alkyl)amino;

R₄ represents from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, haloC₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, aminosulfonyl, and mono- and di-(C₁-C₈alkyl)aminosulfonyl;

B₁ is O, NH or S;

D is -C(=O)- or C₂-C₃alkyl, unsubstituted or substituted with a keto group; and


B₂ is:

- (a) O or S; in which case n is 1, and R_c is hydrogen, PO₃H₂, PO₃H(alkyl), PO₃(alkyl)₂, C₁-C₆alkyl, or C₂-C₆alkyl ether, each of which alkyl moiety is substituted with from 0 to 3 substituents independently selected from R_d; or

- (b) N, in which case n is 2, and

- (i) R_c is independently chosen at each occurrence from hydrogen and C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl, each of which is substituted with from 0 to 3 substituents selected from R_d ; or
- (ii) both R_c moieties are joined to form, with B_2 , a 5- to 8-membered heterocycloalkyl that is substituted with from 0 to 3 substituents selected from R_d ; and
- each R_d is independently:

- (i) halogen, hydroxy, cyano, amino, nitro, $-COOH$; and
- (ii) C_1 - C_4 alkyl, C_1 - C_4 alkenyl, C_1 - C_4 alkynyl, C_1 - C_4 alkoxy, C_1 - C_4 alkanoyl, C_2 - C_4 alkoxycarbonyl, C_2 - C_8 alkanoyloxy, C_1 - C_4 alkylthio, C_2 - C_4 alkyl ether, or mono- or di- $(C_1$ - C_4 alkyl)amino, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino and $-COOH$; and
- wherein the group designated:



comprises at least one carboxylic acid, phosphate or phosphonate group.

27. (Original) A compound according to claim 26, wherein;

B_1 is O; and

either:

(i) D is $-CH_2-CH_2-$ and $-B_2-(R_c)_n$ is:

(a) $-COOH$, $-O-PO_3H_2$, or $-PO_3H_2$; or

(b) pyrrolidine, piperidine, piperazine or morpholine, each of which is substituted with $-COOH$; or

(ii) D is $-CH_2-C(=O)-$ and $-B_2-(R_c)_n$ is:

(a) $-OH$; or

(b) pyrrolidine, piperidine, piperazine or morpholine, each of which is substituted with $-COOH$.

28-29. (Cancelled).

30. (Original) A compound or pharmaceutically acceptable form thereof according to claim 1 wherein the compound has an IC_{50} value of 10 nanomolar or less in a capsaicin receptor calcium mobilization assay.

31. (Original) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable form thereof according to claim 1 in combination with a physiologically acceptable carrier or excipient.

32. (Cancelled).

33. (Original) A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound or pharmaceutically acceptable form thereof according to claim 1, and thereby reducing calcium conductance of the capsaicin receptor.

34-40. (Cancelled).

41. (Original) A method for inhibiting binding of vanilloid ligand to a capsaicin receptor *in vitro*, the method comprising contacting capsaicin receptor with at least one compound or pharmaceutically acceptable form thereof according to claim 1, under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to capsaicin receptor.

42. (Original) A method for inhibiting binding of vanilloid ligand to capsaicin receptor in a patient, comprising contacting cells expressing capsaicin receptor with at least one compound or pharmaceutically acceptable form thereof according to claim 1, in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

43-44. (Cancelled).

45. (Original) A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of at least one compound or pharmaceutically acceptable form thereof according to claim 1, and thereby alleviating the condition in the patient.

46-48. (Cancelled).

49. (Original) A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound or pharmaceutically acceptable form thereof according to claim 1, and thereby alleviating pain in the patient.

50-55. (Cancelled).

56. (Original) A method for treating itch in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1, and thereby alleviating itch in the patient.

57. (Original) A method for treating cough or hiccup in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1, and thereby alleviating cough or hiccup in the patient.

58. (Original) A method for treating urinary incontinence in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1, and thereby alleviating urinary incontinence in the patient.

59. (Original) A method promoting weight loss in an obese patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or pharmaceutically acceptable form thereof according to claim 1, and thereby promoting weight loss in the patient.

60-73. (Cancelled).